Repros Therapeutics Inc (RPRX) 8.76 $RPRX
Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 5:15PM CST
Repros Therapeutics Inc. (RPRX) submitted a NDA for its lead candidate, Androxal.
RPRX: 8.76 (+0.09), ABBV: 58.05 (+1.00), AMAG: 41.49 (+0.23), CELG: 115.88 (+0.16)
Repros submits NDA to US FDA for Androxal for secondary hypogonadism in overweight men
M2 - Tue Feb 03, 4:40AM CST
Drug company Repros Therapeutics (NasdaqCM:RPRX) announced on Monday that it submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead product candidate, Androxal.
RPRX: 8.76 (+0.09)
Update: NDA For Androxal Filed
Samreen Agha - at Seeking Alpha - Tue Feb 03, 4:08AM CST
RPRX: 8.76 (+0.09)
Repros Submits New Drug Application to FDA for Androxal (R)
GlobeNewswire - Mon Feb 02, 9:05AM CST
Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today reported that it has electronically submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Androxal(R), the Company's lead product candidate. Androxal(R) is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound. The Company is developing Androxal(R) for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Androxal(R) is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.
RPRX: 8.76 (+0.09)
Repros submits NDA for Androxal
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 8:43AM CST
RPRX: 8.76 (+0.09)
Now May Be The Time To Buy Repros Therapeutics
Samreen Agha - at Seeking Alpha - Sat Jan 03, 8:45AM CST
RPRX: 8.76 (+0.09)
Uptrend Call Working As Repros Therapeutics Stock Rises 14.3% (RPRX)
Comtex SmarTrend(R) - Wed Dec 31, 9:27AM CST
SmarTrend identified an Uptrend for Repros Therapeutics (NASDAQ:RPRX) on November 7th, 2014 at $8.96. In approximately 2 months, Repros Therapeutics has returned 14.35% as of today's recent price of $10.24.
RPRX: 8.76 (+0.09)
Repros Gains on Positive Updates on the Status of Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:20PM CST
Repros Therapeutics (RPRX) announced the submission of a complete response to the guidance regarding the expected NDA submission for Androxal.
MDCO: 29.79 (+0.91), RPRX: 8.76 (+0.09), ABBV: 58.05 (+1.00), AMAG: 41.49 (+0.23)
Repros set for gap up at the open
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 7:58AM CST
RPRX: 8.76 (+0.09)
Repros initiates trials assessing Proellex in uterine fibroids
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 4:03PM CST
RPRX: 8.76 (+0.09)
Repros moving forward with Androxal NDA
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 3:40PM CST
RPRX: 8.76 (+0.09)
Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble
at The Street - Mon Dec 29, 3:25PM CST
Sears Hometown and Outlet Stores Inc (NASDAQ:SHOS), Celladon Corp (NASDAQ:CLDN) and Repros Therapeutics Inc (NASDAQ:RPRX) are gaining this Monday. Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU),¿...
RIGP: 15.88 (+0.63), RPRX: 8.76 (+0.09), CLDN: 16.45 (-0.05), SSE: 5.23 (+0.22), SHOS: 12.86 (+0.47)
Repros Updates Androxal(R) Global Regulatory Status
GlobeNewswire - Mon Dec 29, 3:20PM CST
-- Full response to November meeting submitted to FDA
RPRX: 8.76 (+0.09)
Repros Initiates Two Phase 2B Uterine Fibroid Studies
GlobeNewswire - Mon Dec 29, 3:15PM CST
-- Low dose oral Proellex study in women with fibroids and heavy menstrual bleeding initiated
RPRX: 8.76 (+0.09)
Repros wins Androxal patent dispute
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 8:26AM CST
RPRX: 8.76 (+0.09)
Court Rules Inventors Correctly Named on Androxal(R) Patents
GlobeNewswire - Mon Dec 29, 8:23AM CST
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced a federal judge in Texas has issued a definitive ruling finding correct inventorship for two Repros Therapeutics Androxal(R) patents, thus confirming that Repros Therapeutics is the sole and rightful owner of the patents, U.S. Patent No. 7,759,360 (the "'360 patent"
and U.S. Patent No. 7,737,185 (the "'185 patent" .
RPRX: 8.76 (+0.09)
Repros +3.8% after favorable summary judgment
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 9:50AM CST
RPRX: 8.76 (+0.09)
5 Stocks Poised for Breakouts: RetailMeNot, Repros and More
at The Street - Fri Dec 19, 12:29PM CST
These are the stocks that often go on to make monster moves to the upside.
QEPM: 16.66 (+0.36), BDR: 1.71 (-0.02), CYBR: 52.52 (+6.83), SALE: 16.41 (+0.13), RPRX: 8.76 (+0.09)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 6.07 (+0.13), DNDN: 0.13 (-0.02), RTRX: 13.92 (+0.44), CYTR: 2.96 (+0.23), RPRX: 8.76 (+0.09), GALE: 1.68 (+0.06), AEGR: 25.15 (+0.88)
Earnings Look Back: Repros Therapeutics Is Down 4.7% Since Reporting Quarterly Results 2 Weeks Ago (RPRX)
Comtex SmarTrend(R) - Mon Nov 24, 9:51AM CST
When Repros Therapeutics (NASDAQ:RPRX) reported earnings two weeks ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.39 on sales of $1.0 thousand. The company actually reported a loss of $0.32 per share on sales of $2.0 thousand, beating EPS estimates by $0.07 and matching revenue estimates. Since the company's report, shares of Repros Therapeutics have fallen from $9.22 to $8.79, representing a loss of 4.7% in the past 14 days.
RPRX: 8.76 (+0.09)
Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 5:15PM CST
Repros Therapeutics Inc. (RPRX) submitted a NDA for its lead candidate, Androxal.
RPRX: 8.76 (+0.09), ABBV: 58.05 (+1.00), AMAG: 41.49 (+0.23), CELG: 115.88 (+0.16)
Repros submits NDA to US FDA for Androxal for secondary hypogonadism in overweight men
M2 - Tue Feb 03, 4:40AM CST
Drug company Repros Therapeutics (NasdaqCM:RPRX) announced on Monday that it submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead product candidate, Androxal.
RPRX: 8.76 (+0.09)
Update: NDA For Androxal Filed
Samreen Agha - at Seeking Alpha - Tue Feb 03, 4:08AM CST
RPRX: 8.76 (+0.09)
Repros Submits New Drug Application to FDA for Androxal (R)
GlobeNewswire - Mon Feb 02, 9:05AM CST
Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today reported that it has electronically submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Androxal(R), the Company's lead product candidate. Androxal(R) is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound. The Company is developing Androxal(R) for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Androxal(R) is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. Secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general.
RPRX: 8.76 (+0.09)
Repros submits NDA for Androxal
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 8:43AM CST
RPRX: 8.76 (+0.09)
Now May Be The Time To Buy Repros Therapeutics
Samreen Agha - at Seeking Alpha - Sat Jan 03, 8:45AM CST
RPRX: 8.76 (+0.09)
Uptrend Call Working As Repros Therapeutics Stock Rises 14.3% (RPRX)
Comtex SmarTrend(R) - Wed Dec 31, 9:27AM CST
SmarTrend identified an Uptrend for Repros Therapeutics (NASDAQ:RPRX) on November 7th, 2014 at $8.96. In approximately 2 months, Repros Therapeutics has returned 14.35% as of today's recent price of $10.24.
RPRX: 8.76 (+0.09)
Repros Gains on Positive Updates on the Status of Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:20PM CST
Repros Therapeutics (RPRX) announced the submission of a complete response to the guidance regarding the expected NDA submission for Androxal.
MDCO: 29.79 (+0.91), RPRX: 8.76 (+0.09), ABBV: 58.05 (+1.00), AMAG: 41.49 (+0.23)
Repros set for gap up at the open
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 7:58AM CST
RPRX: 8.76 (+0.09)
Repros initiates trials assessing Proellex in uterine fibroids
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 4:03PM CST
RPRX: 8.76 (+0.09)
Repros moving forward with Androxal NDA
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 3:40PM CST
RPRX: 8.76 (+0.09)
Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble
at The Street - Mon Dec 29, 3:25PM CST
Sears Hometown and Outlet Stores Inc (NASDAQ:SHOS), Celladon Corp (NASDAQ:CLDN) and Repros Therapeutics Inc (NASDAQ:RPRX) are gaining this Monday. Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU),¿...
RIGP: 15.88 (+0.63), RPRX: 8.76 (+0.09), CLDN: 16.45 (-0.05), SSE: 5.23 (+0.22), SHOS: 12.86 (+0.47)
Repros Updates Androxal(R) Global Regulatory Status
GlobeNewswire - Mon Dec 29, 3:20PM CST
-- Full response to November meeting submitted to FDA
RPRX: 8.76 (+0.09)
Repros Initiates Two Phase 2B Uterine Fibroid Studies
GlobeNewswire - Mon Dec 29, 3:15PM CST
-- Low dose oral Proellex study in women with fibroids and heavy menstrual bleeding initiated
RPRX: 8.76 (+0.09)
Repros wins Androxal patent dispute
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 8:26AM CST
RPRX: 8.76 (+0.09)
Court Rules Inventors Correctly Named on Androxal(R) Patents
GlobeNewswire - Mon Dec 29, 8:23AM CST
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced a federal judge in Texas has issued a definitive ruling finding correct inventorship for two Repros Therapeutics Androxal(R) patents, thus confirming that Repros Therapeutics is the sole and rightful owner of the patents, U.S. Patent No. 7,759,360 (the "'360 patent"
and U.S. Patent No. 7,737,185 (the "'185 patent" . RPRX: 8.76 (+0.09)
Repros +3.8% after favorable summary judgment
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 9:50AM CST
RPRX: 8.76 (+0.09)
5 Stocks Poised for Breakouts: RetailMeNot, Repros and More
at The Street - Fri Dec 19, 12:29PM CST
These are the stocks that often go on to make monster moves to the upside.
QEPM: 16.66 (+0.36), BDR: 1.71 (-0.02), CYBR: 52.52 (+6.83), SALE: 16.41 (+0.13), RPRX: 8.76 (+0.09)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 6.07 (+0.13), DNDN: 0.13 (-0.02), RTRX: 13.92 (+0.44), CYTR: 2.96 (+0.23), RPRX: 8.76 (+0.09), GALE: 1.68 (+0.06), AEGR: 25.15 (+0.88)
Earnings Look Back: Repros Therapeutics Is Down 4.7% Since Reporting Quarterly Results 2 Weeks Ago (RPRX)
Comtex SmarTrend(R) - Mon Nov 24, 9:51AM CST
When Repros Therapeutics (NASDAQ:RPRX) reported earnings two weeks ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.39 on sales of $1.0 thousand. The company actually reported a loss of $0.32 per share on sales of $2.0 thousand, beating EPS estimates by $0.07 and matching revenue estimates. Since the company's report, shares of Repros Therapeutics have fallen from $9.22 to $8.79, representing a loss of 4.7% in the past 14 days.
RPRX: 8.76 (+0.09)
